经动脉灌注化疗对乳腺癌受体的影响-第三军医大学学报.docVIP

经动脉灌注化疗对乳腺癌受体的影响【摘要】 目的 探讨经动脉灌注化疗对乳腺癌雌孕激素受体表达的影响。方法 应用 RT-PCR ) 和免疫组化方法检测62例乳腺癌患者经动脉灌注化疗前后的雌孕激素受体表达情况。 结果 62 例患者中例患者升高48.4% ), 25例患者孕例患者雌孕激素受升高免疫组化 26(41. 9%)例患者雌激素受体表达水平升高，其中14例（22. 6%）由阴性转为阳性；20例（32. 3%）孕激素受体表达水平升高，其中14 例（22. 6%）由阴性转为阳性；16例（25. 8%）雌孕激素受体表达同时升高，其中8例（12. 9%）由雌孕激素受体双阴性转变为雌孕激素受体双阳性。结论 经动脉灌注化疗影响雌孕激素受体的表达；经动脉灌注化疗后应重新检测雌孕激素受体，为后续治疗和判断预后提供指导。 关键词 乳腺肿瘤受体雌激素孕激素类经动脉灌注化疗Effect of transarterial infusion chemotherapy on estrogen and progesterone receptors in breast carcinoma Abstract Objective To investigate the effect of transarterial infusion ( TAI ) chemotherapy on estrogen receptor（ ER ）and progesterone receptor（ PR ）expressions in breast carcinoma.Materials and methods 62 samples from patients with breast carcinoma were selected in this study. ER and PR mRNAs levels in the samples were detected by RT-PCR. Immunohistochemistry was employed to determine ER and PR proteins expressions of samples before and after TAI chemotherapy. Results RT-PCR results ER mRNA level increased in 30 patients（4.4%）R mRNA level increased in 25 patients（%）. Meanwhile, both ER and PR mRNAs levels increased in 20 patients( 32.3% ). Immunohistochemistry results indicated that ER level was up-regulated in 26（41. 9%）out of 62 cases，PR level was up-regulated in 21（32. 3%）. Both ER level and PR level were up-regulated in 16（25.8%）out of 62 cases. Conclusions Arterial intubation chemotherapy may effect mRNA and protein level of the hormone receptors. ER and PR expression levels should be determined again after the transarterial infusion chemotherapy, which will provide a guide for the following treatment and prognosis judgement. Key words Breast neoplasms; Receptors; estrogen; Progestation hormones; transarterial infusion chemotherapy 前言 内分泌治疗是乳腺癌综合治疗的重要手段之一，雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）检测对于内分泌治疗的疗效预测和乳腺癌预后判断有重要意义[1]。新辅助化疗作为一种新的局部进展期乳腺癌治疗策略，取得了令人瞩目的成绩[2]。而经动脉插管灌注化疗可以明显提高抗癌药物在癌组织、周围组织及其淋巴结中的药物浓度[3]。本研究通过检测经动脉灌注化疗前后雌孕激素受体表达情况，探讨其对雌孕激素受体表达的影响，及其对于后续治疗和预后判断的指导意义